Company Profile
Humacyte Stock Price, News & Catalysts
- Ticker:
- HUMA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.64 USD (-5.75%)
Close
Last updated: August 21, 2026
309M USD
Market cap
Why the stock is moving
The latest monitored company update is “Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions.” The corresponding closing-price reaction is not yet available.
Company overview
Bioengineered Human Tissue Platform
Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale.
SYMVESS
SYMVESS is an FDA-approved acellular tissue-engineered vessel for urgent arterial repair after extremity vascular trauma. It is Humacyte's first commercial product and validates the broader tissue platform.
Hemodialysis Access
The Phase 3 V012 study compared the vessel with autologous arteriovenous fistulas for hemodialysis access in women. Positive results form the basis for a planned supplemental BLA.
Coronary Program
Humacyte's coronary tissue-engineered vessel is being developed as an off-the-shelf conduit for coronary artery bypass grafting. The FDA has cleared the IND for a first-in-human Phase 2a study.
Broader Vascular Applications
Additional development areas include peripheral artery disease, pediatric heart surgery, type 1 diabetes, and other cell and tissue applications.
Future catalysts
- Initiation of a Phase 2a study of the coronary tissue-engineered vessel in coronary artery bypass grafting in the third quarter of 2026.
- Submission of a supplemental BLA for the acellular tissue-engineered vessel in hemodialysis access in the second half of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Humacyte (HUMA)?
Humacyte (HUMA) most recently closed at 0.64 USD, a -5.75% move versus the previous session.
What is the market cap of Humacyte (HUMA)?
Humacyte currently has a market capitalization of 309M USD on BioPharmSignal.
What does Humacyte do?
Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale. SYMVESS SYMVESS is an FDA-approved acellular tissue-engineered vessel for urgent...
On which exchange is HUMA stock listed?
Humacyte (HUMA) is associated with NASDAQ, United States, Biopharma.
What is Bioengineered?
Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells.
Which conditions is Humacyte targeting with Bioengineered?
Humacyte is associated with diabetes based on its company overview and current catalyst commentary.
How does Humacyte describe recent progress with Bioengineered?
Initiation of a Phase 2a study of the coronary tissue-engineered vessel in coronary artery bypass grafting in the third quarter of 2026. Submission of a supplemental BLA for the acellular tissue-engineered vessel in hemodialysis access in the second half of 2026.
What is Human?
Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells.